JP2009524422A5 - - Google Patents

Download PDF

Info

Publication number
JP2009524422A5
JP2009524422A5 JP2008551872A JP2008551872A JP2009524422A5 JP 2009524422 A5 JP2009524422 A5 JP 2009524422A5 JP 2008551872 A JP2008551872 A JP 2008551872A JP 2008551872 A JP2008551872 A JP 2008551872A JP 2009524422 A5 JP2009524422 A5 JP 2009524422A5
Authority
JP
Japan
Prior art keywords
polypeptide
binding
terminal
domain
binding complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008551872A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009524422A (ja
Filing date
Publication date
Priority claimed from GBGB0601513.5A external-priority patent/GB0601513D0/en
Application filed filed Critical
Publication of JP2009524422A publication Critical patent/JP2009524422A/ja
Publication of JP2009524422A5 publication Critical patent/JP2009524422A5/ja
Pending legal-status Critical Current

Links

JP2008551872A 2006-01-25 2007-01-25 結合分子3 Pending JP2009524422A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0601513.5A GB0601513D0 (en) 2006-01-25 2006-01-25 Binding molecules 3
PCT/GB2007/000258 WO2007085837A1 (en) 2006-01-25 2007-01-25 Binding molecules

Publications (2)

Publication Number Publication Date
JP2009524422A JP2009524422A (ja) 2009-07-02
JP2009524422A5 true JP2009524422A5 (enExample) 2010-03-11

Family

ID=36060850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008551872A Pending JP2009524422A (ja) 2006-01-25 2007-01-25 結合分子3

Country Status (13)

Country Link
US (1) US20090169548A1 (enExample)
EP (1) EP1989229A1 (enExample)
JP (1) JP2009524422A (enExample)
KR (1) KR20080106201A (enExample)
CN (1) CN101472946A (enExample)
AU (1) AU2007209130A1 (enExample)
BR (1) BRPI0706737A2 (enExample)
CA (1) CA2637945A1 (enExample)
GB (1) GB0601513D0 (enExample)
RU (1) RU2008134519A (enExample)
TW (1) TW200808824A (enExample)
WO (1) WO2007085837A1 (enExample)
ZA (1) ZA200806492B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8629246B2 (en) 2007-09-26 2014-01-14 Ucb Pharma S.A. Dual specificity antibody fusions
WO2010035012A1 (en) 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
MX2012003396A (es) 2009-09-16 2012-04-10 Genentech Inc Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos.
RU2013110875A (ru) 2010-08-24 2014-09-27 Ф.Хоффманн-Ля Рош Аг БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
AR085403A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos
EP2681239B8 (en) 2011-02-28 2015-09-09 F. Hoffmann-La Roche AG Antigen binding proteins
AU2012311286B2 (en) 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CA2850291A1 (en) 2011-09-29 2013-04-04 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
DK2771364T3 (da) * 2011-10-27 2019-08-19 Genmab As Fremstilling af heterodimere proteiner
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US10946104B2 (en) 2012-01-13 2021-03-16 Apo-Tb.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
CN102851338A (zh) * 2012-07-25 2013-01-02 苏州康宁杰瑞生物科技有限公司 利用电荷排斥作用制备同二聚体蛋白混合物的方法
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
GB2518221A (en) * 2013-09-16 2015-03-18 Sergej Michailovic Kiprijanov Tetravalent antigen-binding protein molecule
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
RU2016115866A (ru) 2013-10-11 2017-11-16 Ф. Хоффманн-Ля Рош Аг Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
CN107001482B (zh) * 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
JP7628764B2 (ja) 2015-09-29 2025-02-12 アムジエン・インコーポレーテツド Asgr阻害剤
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
SG11202003114UA (en) * 2017-10-04 2020-05-28 Amgen Inc Transthyretin immunoglobulin fusions
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
CN114206942A (zh) 2019-06-07 2022-03-18 美国安进公司 双特异性结合构建体
CN113461824A (zh) * 2020-03-31 2021-10-01 普米斯生物技术(珠海)有限公司 一种构建多特异性抗体的平台
AU2021283933A1 (en) 2020-06-04 2023-01-05 Amgen Inc. Bispecific binding constructs
WO2022120033A1 (en) 2020-12-03 2022-06-09 Amgen Inc. Immunoglobuline constructs with multiple binding domains

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ121599A3 (cs) * 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
WO2002002781A1 (en) * 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
EP1558647B1 (en) * 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1978032A3 (en) * 2004-07-22 2009-02-18 Erasmus University Medical Center Rotterdam Binding molecules
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof

Similar Documents

Publication Publication Date Title
JP7244567B2 (ja) 新規結合ドメイン含有ポリペプチドおよびその使用
JP2020517294A5 (enExample)
Lu et al. Di-diabody: a novel tetravalent bispecific antibody molecule by design
JP5150488B2 (ja) Fc領域含有タンパク質を精製する方法
RU2019120720A (ru) Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
IL275743A (en) New bispecific format suitable for use in high-through-put screening
JP2019068822A5 (enExample)
JP2021042257A5 (enExample)
JP2011526794A5 (enExample)
JP2010511397A5 (enExample)
CA2468583A1 (en) Self-assembling multimeric binding complexes derived from ab5 toxin family members
JP2022171730A5 (enExample)
JP2017518748A5 (enExample)
RU2015129640A (ru) Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1
JP2016527314A5 (enExample)
JP2019500862A5 (enExample)
HRP20140760T1 (hr) Citotoksiäśni imunoglobulin
WO2003057829A3 (en) Methods of generating multispecific, multivalent agents from vh and vl domains
JP2010531144A5 (enExample)
JP2014525735A5 (enExample)
JP2009539412A5 (enExample)
RU2015152077A (ru) Тримерные антигенсвязывающие молекулы
JP2005506064A5 (enExample)
WO2009010539A2 (en) Receptor for interleukin-6 (il-6) from macaca fascicularis
JP2013163673A5 (enExample)